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BACKGROUND: Women are less likely to receive primary percutaneous coronary intervention (pPCI) than men. A potential rea-
son is risk aversion because of the worse outcomes with pPCI among women. However, whether pPCI is associated with a 
comparable mortality benefit in men and women remains unknown.
METHODS AND RESULTS: We selected patients admitted with a principal diagnosis of ST- segment– elevation myocardial infarc-
tion in the National Inpatient Sample (2016– 2018). We used propensity- score matching to calculate average treatment effects 
of pPCI for in- hospital mortality, major complications, length of stay, and cost. As a sensitivity analysis, we used logit models 
followed by a marginal command to calculate the average marginal effect. We included 413 500 weighted hospitalizations 
(30.7% women, 69.3% men). Women had more comorbidities except smoking and prior sternotomy. Compared with men, 
women were less likely to undergo angiography (81.0% versus 87.0%; adjusted odds ratio [OR], 0.77; 95% CI, 0.74– 0.81; 
P<0.001) or pPCI (74.0% versus 82.0%; adjusted OR, 0.76; 95% CI, 0.73– 0.79; P<0.001). There were no significant differ-
ences in average treatment effects of pPCI on mortality between men (−8.4% [−9.3% to −7.6%], P<0.001), and women (−9.5% 
[−10.8% to −8.3%], P<0.001) (P interaction=0.16). This persisted in age- stratified analyses (≥85, 65– 84, 45– 64, <45 years) 
and sensitivity analysis, excluding emergent admissions. The average treatment effects of pPCI on major complications were 
comparable except for acute stroke, leaving against medical advice, and palliative encounter. There were no differences in 
the average treatment effects of pPCI on length of stay, but the proportional increase in cost with pPCI was higher in women.
CONCLUSIONS: pPCI results in a comparable reduction in in- hospital mortality in men and women. Nonetheless, risk- adjusted 
rates of pPCI remain lower in women in contemporary US practice.
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Disparities in the management of ST- segment– elevation myocardial infarction (STEMI) between men and women are well documented. Women 
presenting with STEMI are less likely to receive inva-
sive management, primary percutaneous coronary 
intervention (pPCI), or preventive medication at dis-
charge.1– 10 Reasons for this disparity are multifacto-
rial and include differences in risk profile, symptom 
complex, and timing of presentation (typically more de-
layed among women).11– 14 In addition, pPCI is thought 
to be associated with worse outcomes in women, 
which may play a role in the lower rates of its provision 
among them, although data on sex- specific pPCI out-
comes are conflicting.1,9,11– 16 However, previous studies 
documenting worse outcomes of pPCI in women only 
compared absolute mortality and not the differential 
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treatment effect of pPCI on outcomes in men versus 
women. The latter approach, referred to as treatment 
effect, has been recently used to assess whether 
high- risk patients derive a comparable benefit from a 
specific cardiovascular intervention (eg, percutaneous 
coronary intervention [PCI]) than low- risk patients.17,18 
We used a contemporary nationwide database to test 
the hypothesis that pPCI is associated with a compa-
rable effect on short- term mortality in men and women. 
Hence, avoiding pPCI in women based on their higher 
perceived risks is not justified.
METHODS
Study Data
Our study used the National Inpatient Sample (NIS) 
(January 1, 2016 to December 31, 2018). The NIS is 
the largest publicly available all- payer inpatient data-
base in the United States. The annual NIS sample en-
compasses ~8  million discharges, representing 20% 
of inpatient stays across different hospital types and 
geographic regions.19 National estimates of the US 
population are calculated using standardized sampling 
and weighting methods provided by the Agency for 
Healthcare Research and Quality. The NIS includes 
detailed information about demographics, inpatient 
diagnoses and procedures, total costs, primary pay-
ers, length of stay, and hospital characteristics and has 
been used extensively to assess outcomes of STEMI, 
pPCI, and other cardiovascular interventions.1,2,20– 23 
Because data are publicly available and deidenti-
fied, this study was deemed exempt from institutional 
board review approval. The authors of this article can-
not share the NIS data directly because the Agency 
for Healthcare Research and Quality imposes restric-
tions on data sharing. Please refer to the Data Use 
Agreement available on www.hcup- us.ahrq.gov for 
more information.
Study Population
Hospital stays for adults (aged ≥18 years) with a pri-
mary diagnosis of STEMI were identified using the 
International Classification of Diseases, Tenth Revision, 
Clinical Modification (ICD- 10- CM) codes (Table  S1). 
Patients who were coded to have STEMI as a second-
ary diagnosis were excluded. We also excluded those 
who were transferred to another hospital to avoid du-
plication of records.
Study End Points
We investigated the effect of pPCI on clinical out-
comes in men and women. The primary end point was 
in- hospital mortality. Secondary end points included 
acute stroke, vascular complications, gastrointestinal 
bleeding, blood transfusion, mechanical ventilation, 
palliative care use, home discharge, and transfer to a 
skilled nursing facility. We also compared the length of 




Categorical variables were presented as percentages 
and compared using the χ2 test. Continuous vari-
ables with a normal distribution (eg, age) were pre-
sented as means with a 95% CI and compared using 
a t test. Continuous variables with a skewed distribu-
tion (eg, cost) were presented as medians with in-
terquartile range and compared using the Wilcoxon 
rank sum test. We used quantile linear regression 
followed by Stata’s margins command to predict ad-
justed medians of the length of stay and costs.24,25 
Total costs were adjusted for inflation using the 
Consumer Price Index and were calculated in 2018 
US dollars. Because the data were missing in <1% 
for all variables except for race (~4%) and household 
income (~2%), we deleted missing data and did not 
impute them using complex statistical methods. We 




• This study documents that in the setting of 
ST- segment– elevation myocardial infarction, 
women are less likely to undergo primary per-
cutaneous coronary intervention than men, de-
spite both sexes deriving comparable clinical 
benefit from the procedure.
• This treatment gap persists even after adjust-
ment for differences in demographics and co-
morbidities between men and women.
What Are the Clinical Implications?
• Efforts are needed to identify effective strate-
gies to bridge this gap.
Nonstandard Abbreviations and Acronyms
AME average marginal effect
ATE average treatment effect
NIS National Inpatient Sample
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Risk- Adjusted Differences in 
Management Patterns
To assess the likelihood of women receiving standard 
of care treatment (angiography, pPCI), we constructed 
a multivariate logistic regression model to account for 
differences in baseline characteristics between men and 
women. Multiple variables were included in the model: 
age, race, chronic renal insufficiency, chronic obstructive 
pulmonary disease, primary payer, household income, 
hypertension, diabetes, heart failure, atrial fibrillation, pe-
ripheral vascular disease, prior stroke, prior sternotomy, 
conduction disorder, anemia, liver disease, obesity, ma-
lignancy, dementia, chronic obstructive pulmonary dis-
ease, and elective admission status. The likelihood of 
undergoing angiography or pPCI among women versus 
men was presented as an odds ratio [OR] with 95% CI.
Average Treatment Effect
We estimated the average treatment effect (ATE) of PCI 
in each group using propensity- score matching.17,26– 28 
Briefly, we used a logistic regression model to predict 
each hospitalization’s propensity score using the fol-
lowing covariates: age, chronic renal insufficiency, 
race, insurance (Medicaid/Medicare), household in-
come, hypertension, diabetes, heart failure, atrial fibril-
lation, vascular disease, prior stroke, prior sternotomy, 
conduction disorder, anemia, liver disease, obesity, 
malignancy, dementia, chronic obstructive pulmonary 
disease, and admission status (Figure S1). Each hos-
pitalization was matched to a single hospitalization 
from the opposite group (pPCI versus no PCI) whose 
propensity score is closest. The ATE was computed 
by taking the average difference in outcomes between 
each hospitalization and its match. We repeated this 
method for each clinical outcome. A negative ATE co-
efficient indicates that pPCI reduces the rate of that 
outcome and vice versa. We compared the ATE coef-
ficients between men and women using the following 
formula Z = (b1 − b2)∕(SEb12 + SEb22). Where b1 and 
b2 are the ATE coefficients in each group, and SEb1 
and SEb2 are the corresponding standard errors. P- 
value was calculated from the corresponding Z score.
To ensure the robustness of our findings, we per-
formed several sensitivity analyses. To account for clus-
tering within hospitals, we used a different method to 
calculate the treatment effect of pPCI in women versus 
men (logit model followed by the average marginal ef-
fects [AMEs]).25,29,30 We first fitted a population- averaged 
logit model using the exchangeable correlation struc-
ture and robust variance- covariance estimation in this 
method.30 The model was adjusted for the same co-
variates included in the first propensity- score match-
ing method. We followed this by calculating average 
marginal effect (Stata’s margins command). For every 
hospitalization, the margins command uses the logit 
model to predict the probability of the outcome (eg, 
in- hospital mortality) in 2 scenarios: if the patient had 
received PCI and did not receive PCI, leaving all other 
covariates values as is. The average marginal effects 
are then computed by taking the average difference be-
tween these 2 probabilities. We repeated this method 
for each clinical outcome. A negative marginal effects 
coefficient indicates that PCI reduces the probability 
of that outcome and vice versa. We used the above Z 
equation to compare the AMEs coefficients between 
the 2 groups. To account for the differences in the 
pathophysiology of a portion of STEMI cases in women 
versus men, we (1) performed age- stratified subgroup 
analyses (>85, 65– 84, 45– 64, <45 years), and (2) re-
peated the analysis excluding patients with diagnosis 
code for coronary dissection and Takotsubo cardiomy-
opathy, because both are known to be more frequent in 
women than in men. We also performed another sen-
sitivity analysis excluding patients who had an elective 
admission and subsequently developed an in- hospital 
STEMI during the hospitalization. Finally, we also chose 
irritable bowel syndrome and infectious arthropathies 
as falsification end points because they are physiologi-
cally less likely to be associated with or affected by PCI.
RESULTS
Baseline and Procedural Characteristics
A total of 413 500 weighted STEMI hospitalizations were 
included in the study, of which 126 885 (30.7%) involved 
women and 286 530 (69.3%) involved men. Compared 
with men, women were older (67.6 versus 61.7 years), 
and more likely to have Medicare/Medicaid insurance 
(69.0% versus 50.0%), and to be in the lowest quartile for 
household income (30.0% versus 26.0%) (P<0.05 for all). 
Women also had higher cardiac and noncardiac comor-
bidities burden except for smoking and prior sternotomy 
(Table 1). Before risk adjustment, women were less likely 
to undergo coronary angiography (81.0% versus 87.0%, 
P<0.001), and less likely to receive pPCI (74.0% versus 
82.0%, P<0.001) (Figure 1) or coronary bypass grafting 
(3.0% versus 4.7%, P<0.001) (Table 2). After adjustment 
for demographics, socioeconomic, and clinical risk fac-
tors, women had lower odds of undergoing angiogra-
phy (OR 0.78; 95% CI, 0.74– 0.82; P<0.001), or pPCI (OR 
0.76; 95% CI, 0.73– 0.79; P<0.001) compared with men.
Clinical Outcomes of STEMI in Men and 
Women
Patients who underwent pPCI were younger and more 
likely to be treated at teaching or large hospitals in both 
groups. Although most cardiovascular comorbidities 
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pPCI versus those who did not, noncardiovascular co-
morbidities were more frequent among patients who 
did not undergo pPCI (Table 3). Patients who under-
went pPCI had lower in- hospital mortality than those 
not treated with pPCI in both men and women co-
horts. Among women, mortality was 6.5% with pPCI 
versus 20.0% without pPCI (P<0.001). Among men, 
mortality was 4.5% with pPCI versus 16.0% without 
pPCI (P<0.001) (Figure  2). Major complications were 
more common in the no- pPCI subgroups in both co-
horts (Table 4). Women, but not men, who underwent 
pPCI had an increased risk of vascular complications 
(Table 4). Patients who had pPCI were more likely to be 
discharged home than a skilled nursing facility in both 
groups. These differences persisted in age- stratified 
analyses (Tables S2 through S5).
Average Treatment Effects of pPCI
There were no significant differences in the ATEs of 
pPCI on the primary end point (in- hospital mortality) 
between men (−8.4% [−9.3% to −7.6%], P<0.001), 
and women (−9.5% [−10.8% to −8.3%], P<0.001) (P- 
interaction=0.16). The treatment effects of pPCI on 
acute kidney injury, new dialysis requirements, vas-
cular complications, gastrointestinal bleeding, me-
chanical ventilation, and discharge disposition were 
comparable between men and women, as shown in 
Table 5. However, the impact of pPCI on acute stroke 
and the palliative encounter was lower in women than 
in men (Table 5). The impact of pPCI on leaving against 
medical advice was higher in women than in men 
(Table 5). These treatment effects are investigated in 
subgroup analyses stratified by age (>85, 65– 84, 45– 
64, <45  years) (Tables S6 through S9). There were 
no differences in the impact of pPCI on risk- adjusted 
length of stay between men and women. However, the 
Table 1. Baseline Characteristics of the Study Cohort
Baseline 
characteristics Women, n=126 885 Men, n=286 530
Demographics
Age, y, mean (95% CI) 67.6 (67.5– 67.8) 61.7 (61.6– 61.8)







Hospital in southern 
states
42.0% 41.0%
Teaching hospital 66.0% 67.0%








Chronic heart failure 19.0% 14.0%




Prior stroke 6.9% 4.3%
Conduction disorders 9.1% 8.1%
















Figure 1. Rates of coronary angiography and primary 
percutaneous coronary interventions (PCI) among men and 
women admitted with ST- segment– elevation myocardial 
infarction.
 
Table 2. Management of ST- Segment– Elevation 
Myocardial Infarction in Men Versus Women
Management pattern Women, n=126 885 Men, n=286 530
Coronary angiography 81.0% 87.0%
Coronary intervention 74.0% 82.0%
Single vessel intervention 63.0% 69.0%
Multivessel intervention 11.0% 13.0%
Bare- metal stent 7.3% 8.2%
Coronary bypass grafting 3.0% 4.7%
Mechanical support, any 8.2% 10.0%
Intra- aortic balloon pump 6.5% 7.5%
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proportional increase in cost associated with pPCI was 
higher in women than in men (Table 6).
Sensitivity Analyses
1. Using the AMEs methodology, which accounts for 
within- hospital clustering of hospitalizations, the AMEs 
of pPCI on in- hospital mortality were −10% (−11% to 
−9%) in women versus −7.9% (−8.6% to −7.2%) in men 
(P=0.001), suggesting a modestly higher magnitude of 
benefit for pPCI in women versus men. The AMEs 
of pPCI on other outcomes are listed in Table  7.
2. The ATE of pPCI on in- hospital mortality remained 
nonsignificantly different between men and women 
in age- stratified subgroups (>85, 65– 84, 45– 64, 
<45 years) (Table S6– S9).
3. The ATEs of pPCI also remained similar in men and 
women in additional analyses, excluding patients 
with elective admissions and subsequent STEMI. 
However, the ATEs of pPCI were higher in women 
than men after excluding those with coronary 
dissection and Takotsubo cardiomyopathy (Tables 
S10 through S13).
Table 3. Baseline Characteristics of the Study Cohorts Stratified by Sex and Use of pPCI
Baseline characteristics
Women, n=126 885 Men, n=286 530
No pPCI, 26% pPCI, 74% No pPCI, 18% pPCI, 82%
Demographics
Age, y 72.5 (72.1– 72.9) 65.9 (65.7– 66.2) 64.9 (64.6– 65.2) 61.0 (60.8– 61.1)
White race 70.5% 72.6% 68.4% 71.6%
Medicare/Medicaid insurance 77.2% 65.9% 61.3% 47.0%
Lowest quartile income 29.7% 29.4% 28.9% 25.5%
Hospital in Southern states 38.8% 42.6% 40.9% 41.6%
Teaching hospital 61.8% 68.1% 66.2% 67.7%
Large- bed- size hospital 19.3% 14.6% 16.5% 14.6%
Cardiovascular comorbidities
Smoking 16.8% 33.0% 25.4% 34.2%
Hypertension 32.8% 22.2% 30.3% 18.1%
Diabetes 38.7% 40.5% 41.5% 34.8%
Chronic heart failure 28.2% 15.1% 24.1% 11.9%
Atrial fibrillation 22.8% 13.3% 20.7% 11.4%
Peripheral vascular disease 8.7% 6.2% 8.4% 4.4%
Prior stroke 8.7% 6.3% 6.7% 3.8%
Conduction disorders 9.6% 8.9% 10.0% 7.7%
Prior sternotomy 6.4% 3.0% 9.7% 4.0%
Pulmonary hypertension 5.8% 2.9% 3.5% 1.6%
Noncardiovascular comorbidities
Chronic obstructive lung disease 16.2% 12.4% 13.3% 8.3%
Chronic kidney disease 21.6% 11.9% 20.3% 10.0%
Anemia 19.4% 13.7% 14.4% 6.8%
Liver disease 4.7% 3.8% 6.0% 3.9%
Dementia 13.8% 3.5% 5.2% 1.4%
Malignancy 6.3% 3.2% 5.6% 2.5%
Obesity 13.0% 19.5% 14.1% 15.4%
pPCI indicates primary percutaneous coronary intervention.
Figure 2. In- hospital mortality among men and women 
admitted with ST- segment– elevation myocardial infarction 
(STEMI) stratified by the use of primary percutaneous 
coronary intervention (PCI).
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4. Finally, there were no differences in the selected fal-
sification end points between men and women 
(Table S14).
DISCUSSION
The salient finding of this study is that although the es-
timated average treatment effect of pPCI on in- hospital 
morbidity and mortality is similar in men and women 
admitted with STEMI, women remain much less likely 
to receive this standard of care treatment.
Sex differences in the management of myocardial 
infarction are well described in the literature. In STEMI, 
several prior studies have documented that women 
are less likely to receive standard of care treatments, 
including pPCI.1– 10 Our study encompasses a large co-
hort of patients admitted in 2016 to 2018 and shows 
that significant sex differences in the management of 
STEMI persist in contemporary US practice. The ab-
solute difference in the usage rate of pPCI between 
men and women was 8%. Hypothetically, this dis-
parity could be attributed to differences in risk profile 
between women and men presenting with STEMI. 
However, even after adjusting for age, demographics, 
and clinical risk factors, women remained 25% less 
likely to undergo angiography or receive pPCI than 
men. A potential reason for the lower revasculariza-
tion rates among women with pPCI is the notion that 
Table 4. Comparison of Unadjusted Rates of Death and Major Complications Between Men and Women Stratified by pPCI 
Status
Clinical outcomes
Women, n=126 885 Men, n=286 530
No pPCI, 26% pPCI, 74% No pPCI, 18% pPCI, 82%
In- hospital mortality 20.0% 6.5% 16.0% 4.5%
Acute stroke 1.7% 0.9% 1.4% 0.6%
Acute kidney injury 23.0% 13.0% 25.0% 14.0%
New dialysis requirement 0.8% 0.4% 0.8% 0.4%
Vascular complications 0.8% 1.4% 0.8% 0.7%
Gastrointestinal bleeding 2.8% 1.8% 2.6% 1.4%
Blood transfusion 6.5% 4.7% 6.4% 2.8%
Mechanical ventilation 14.0% 9.8% 17.0% 8.9%
Palliative care encounter 13.0% 2.4% 7.4% 1.6%
Left against medical advice 0.9% 0.5% 1.7% 0.9%
Home discharge 49.0% 82.0% 58.0% 88.0%
Nonhome discharge 29.0% 11.0% 25.0% 6.8%
pPCI indicates primary percutaneous coronary intervention.
Table 5. ATE of Primary Percutaneous Coronary Intervention in Men and Women Using Propensity- Score Matching
Clinical outcomes
Women, n=126 885 Men, n=286 530
P value*ATE (95% CI) P value ATE (95% CI) P value
In- hospital mortality −9.5% (−10.8% to −8.3%) <0.001 −8.4% (−9.3% to −7.6%) <0.001 0.16
Acute stroke 0.5% (−0.8% to 1.8%) 0.447 −1.5% (−2.4% to −0.6%) 0.004 0.01
Acute kidney injury −0.6% (−1.1% to 0.0%) 0.034 −0.3% (−0.6% to −0.1%) 0.001 0.43
New dialysis requirement −3.5% (−4.8% to −2.3%) <0.001 −3.9% (−4.8% to −3.0%) <0.001 0.61
Vascular complications −0.1% (−0.4% to 0.1%) 0.363 0.0% (−0.2% to 0.1%) 0.948 0.63
Gastrointestinal bleeding 0.4% (0.0% to 0.8%) 0.055 0.1% (−0.1% to 0.3%) 0.677 0.16
Blood transfusion −0.2% (−0.7% to 0.3%) 0.401 −0.5% (−0.8% to −0.1%) 0.043 0.39
Mechanical ventilation −1.2% (−2.0% to −0.3%) 0.010 −2.1% (−2.6% to −1.5%) <0.001 0.07
Palliative care encounter −3.8% (−5.1% to −2.5%) <0.001 −5.9% (−6.8% to −5.0%) <0.001 0.01
Left against medical advice −6.5% (−7.4% to −5.6%) <0.001 −3.6% (−4.1% to −3.1%) <0.001 <0.001
Home discharge −0.5% (−0.9% to −0.1%) 0.017 −1.0% (−1.3% to −0.6%) <0.001 0.12
Nonhome discharge 25.0% (23.2% to 26.8%) <0.001 24.3% (23.1% to 25.5%) <0.001 0.49
ATE indicates average treatment effect.
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women suffer worse outcomes (and hence derive less 
benefit) from pPCI. To assess whether this is true, we 
used a well- established method (ATE) to compare the 
impact of pPCI on short- term outcomes in men versus 
women. A heterogeneous treatment effect would in-
dicate that one sex derives worse outcomes than the 
other.13,21 Conversely, a homogenous treatment effect 
would suggest that the benefit of pPCI is consistent 
among both sexes. The primary treatment effect of in-
terest was in- hospital mortality, which is known to be 
significantly less among patients with STEMI treated 
with pPCI compared with no pPCI.
The findings of this study confirmed our hypothe-
sis that the magnitude of benefit from pPCI in reduc-
ing mortality is comparable in both men and women. 
However, these findings deserve more elaboration; 
first, women undergoing PCI experience more vas-
cular and bleeding complications and receive more 
blood transfusions than men. Although the ATEs of 
pPCI on those secondary end points were more favor-
able among men, the ATE of pPCI on in- hospital mor-
tality was almost identical in both groups. These data 
disprove the perception that the lower usage of life- 
saving therapies such as pPCI could be attributed to 
risk aversion and call for further efforts to understand 
the reasons for this disparity and identify strategies 
for its mitigation. Second, the treatment effect of pPCI 
remained homogeneous among men and women in 
multiple sensitivity analyses accounting for within- 
hospital clustering and potential differences in the 
pathophysiology and culprit vessel anatomy of STEMI 
between men and women. Finally, the incremental 
cost associated with pPCI versus no pPCI was higher 
among women. Although speculative, this could in-
clude higher use of resources because of bleeding 
and vascular complications (eg, testing, equipment,) 
among women because of possible later presentation 
or delayed treatment.
Table 6. Adjusted Length of Stay and Hospital Costs for Men and Women With ST- Segment– Elevation Myocardial 
Infarction
Resource use
Women, n=126 885 Men, n=286 530
No PCI PCI P value No PCI PCI P value
Length of stay in days, median 
(IQR)*
3 (1– 5) 3 (2– 4) 0.57 3 (1– 6) 2 (2– 3) <0.001
Adjusted predicted median 
length of stay in days†
2.8 2.8 0.99 2.5 2.5 0.99











Adjusted predicted median 
hospital cost in 2018 USD†
$11 340 $21 963 <0.001 $15 069 $22 245 <0.001
IQR indicates interquartile range; PCI, percutaneous coronary intervention; and USD, United States dollars.
*Using Wilcoxon rank sum test.
†Using a quintile regression followed by marginal command to estimate the adjusted predicted median.
Table 7. AME of Primary Percutaneous Coronary Intervention in Men and Women
Clinical outcomes
Women, n=126 885 Men, n=286 530
P value*AME (95% CI) P value AME (95% CI) P value
In- hospital mortality −10.0% (−11.0% to −9.0%) <0.001 −7.9% (−8.6% to −7.2%) <0.001 0.001
Acute stroke 0.9% (−0.2% to 1.9%) 0.097 −1.3% (−2.0% to −0.5%) 0.043 0.001
Acute kidney injury −0.6% (−0.9% to −0.2%) 0.002 −0.4% (−0.6% to −0.1%) 0.042 0.31
New dialysis requirement −3.9% (−4.9% to −2.8%) <0.001 −4.3% (−5.1% to −3.6%) <0.001 0.47
Vascular complications −0.2% (−0.4% to 0.0%) 0.11 −0.1% (−0.2% to 0.1%) 0.113 0.47
Gastrointestinal bleeding 0.6% (0.3% to 1.0%) <0.001 0.0% (−0.2% to 0.2%) 0.520 0.001
Blood transfusion −0.3% (−0.8% to 0.1%) 0.12 −0.4% (−0.7% to −0.1%) 0.029 0.77
Mechanical ventilation −1.1% (−1.8% to −0.4%) 0.002 −2.3% (−2.7% to −1.8%) <0.001 0.007
Palliative care encounter −3.3% (−4.3% to −2.3%) <0.001 −5.4% (−6.2% to −4.6%) <0.001 0.001
Left against medical advice −6.9% (−7.6% to −6.1%) <0.001 −3.6% (−4.0% to −3.1%) <0.001 <0.001
Home discharge −0.6% (−0.9% to −0.2%) 0.001 −0.8% (−1.1% to −0.5%) <0.001 0.22
Nonhome discharge 24.1% (22.6% to 25.5%) <0.001 22.8% (21.7% to 23.8%) <0.001 0.15
AME indicates average marginal effect.
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Limitations
First, the NIS collects data for billing purposes, and 
is subject to miscoding errors. However, coding for 
STEMI and pPCI are directly linked to reimburse-
ment, and hence are less prone to this limitation. 
Besides, we used validated codes that have been 
used extensively in prior studies using the NIS.31,32 
Second, the NIS does not capture pharmacother-
apy, echocardiography, or angiographic data. Thus, 
granular information on the differences in antithrom-
botic regimes, ejection fraction, successful versus 
unsuccessful PCI, and reasons for not performing 
PCI is not available. Third, despite the rigorous use 
of propensity matching and other risk- adjustment 
strategies in this study, the impact of residual and 
unknown confounders could not be eliminated. For 
example, we cannot adjust for patient’s preferences, 
presentation delays, and angiographic findings. 
These variables might have affected the decision to 
pursue or forgo pPCI.
Nonetheless, there is no nationwide clinical data-
base containing adequate information about all po-
tential residual confounders to our knowledge. We 
believe that our findings are relevant to clinical prac-
tice, especially considering that randomized data in 
this population are improbable. Fourth, there are dif-
ferences in the pathophysiology of STEMI between 
men and women, which may impact the allocation of 
treatment. Although we have accounted for most of 
such differences in our sensitivity analyses, there are 
no billing codes for myocardial infarction with non-
obstructive coronary arteries. Hence, we are unable 
to account for patients with this entity completely. 
Finally, the NIS does not contain laboratory values 
or include long- term outcomes beyond hospital dis-
charge. Thus, its findings should be interpreted in 
light of these limitations.
CONCLUSIONS
Among patients admitted with STEMI, pPCI results in 
a similar reduction of in- hospital mortality in men and 
women. Nonetheless, risk- adjusted rates of pPCI re-
main much lower in women than in men in contempo-
rary US practice.
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Disease/ Complication ICD-10-CM 
ST-Elevation Myocardial 
Infarction  
I21.0, I21.01, I21.02, I21.09, I21.1, I21.11, I21.19, I21.2, I21.21, I21.29, I21.3 
Dependence on dialysis Z99.2 
Acute kidney injury N170, N171, N172, N178, N179, N19 
Chronic Kidney disease 
Z992, Z940, Z9115, Z4932, Z4931, Z4902, Z4901, R880, N189, N186, N181, N185, N184, 
N183, N182 
End-Stage Renal Disease 
Codes combination of chronic kidney disease and dependence on renal dialysis excluding 
patients who had codes of acute kidney injury/failure. 
Smoking 
F17200, F17201, F17203, F17208, F17209, F17210, F17211, F17213, F17218, F17219, 
F17220, F17221, F17223, F17228, F17229, F17290, F17291, F17293, F17298, F17299 
Hypertension I10, I11*, I12*, I13*, I15* 
Diabetes mellitus E08-E13, R7302, R7303, R7309, R739, R81, R824, Z4681, Z9641, G3289, G3289 
Chronic heart failure 
I0981, I110, I130, I132, I501, I5020, I5022, I5030, I5032, I5040, I5042, I50810, I50812, 
I50814, I5082, I5083, I5084, I5089, I509 
Atrial fibrillation I480, I481, I482, I4891, I483, I484, I4892, I489, I48 
Peripheral vascular 
disease 
I739, I7389, Z95820, Z9862, Z95828, I700, I701, I70201, I70202, I70203, I70208, I70209, 
I70211, I70212, I70213, I70218, I2581, I70219, I70221, I70222, I70223, I70228, I70229, 
II70231, I70232, I70243, I70244, I70245, I70248, I70249, I70231, I70242, I70291, I70292, 
I70293, I70298, I70299, I7090, I7091, I7092, K551, K558, K559, I6529 
Prior stroke Z8673 
Conduction disorder I444, I445, I4460, I4469, I447, I450, I4510, I4519, I452, I453, I454, I4589, I459 
Prior sternotomy Z951, Z952, Z95811, Z95812 
Pulmonary Hypertension 
I27, I270, I271, I272, I2720, I2721, I2722, I2723, I2724, I2729, I278, I2781, I2782, I2782, 
I2783, I2789, I279,  
COPD J449, J441 
Anemia D50-D53, D55-D59, D60-D61, D63-D64, Z8631 
Liver disease K70-K77, I85, I850, I8500, I8501, I851, I8510, I8511 
Dementia 
F1917, F1027, F0391, F0390, F039, F03, F0151, F0150, F015, F01, F0281, F0280, F1927, 
F1997, F1097 
Obesity E669, E662, E6601, E668, E660, E6609 
Coronary angiogram 
272346, 027234Z, B210010, B2100ZZ, B210110, B2101ZZ, B210Y10, B210YZZ, B211010, 
B2110ZZ, B211110, B2111ZZ, B211Y10, B211YZZ, B212010, B2120ZZ, B212110, 
B2121ZZ, B212Y10, B212YZZ, B213010, B2130ZZ, B213110, B2131ZZ, B213Y10, 
B213YZZ, B2140ZZ, B2141ZZ, B214YZZ, B2150ZZ, B2151ZZ, B215YZZ, B2160ZZ, 
B2161ZZ, B216YZZ, B2170ZZ, B2171ZZ, B217YZZ, B2180ZZ, B2181ZZ, B218YZZ, 
B21F0ZZ, B21F1ZZ, B21FYZZ,  
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Single vessel coronary 
intervention 
02703D6, 02703DZ, 02703E6, 02703EZ, 02703F6, 02703FZ, 02703G6, 02703GZ, 02703Z6, 
02703ZZ, 02704D6, 02704DZ, 02704EZ, 02704F6, 02704FZ, 02704G6, 02704GZ, 02704Z6, 
02704ZZ, 02703E6, 02704E6, 02703E6, 02704E6, 270346, 027034Z, 270356, 027035Z, 




271346, 027134Z, 271356, 027135Z, 271366, 027136Z, 271376, 027137Z, 271446, 027144Z, 
271456, 027145Z, 271466, 027146Z, 271476, 027147Z, 272346, 027234Z, 272356, 027235Z, 
272366, 027236Z, 272376, 027237Z, 272446, 027244Z, 272456, 027245Z, 272466, 027246Z, 
272476, 027247Z, 273346, 027334Z, 273356, 027335Z, 273366, 027336Z, 273376, 027337Z, 
273446, 027344Z, 273456, 027345Z, 273466, 027346Z, 273476, 027347Z, 02713D6, 
02713DZ, 02713EZ, 02713F6, 02713FZ, 02713G6, 02713GZ, 02713Z6, 02713ZZ, 02714D6, 
02714DZ, 02714EZ, 02714F6, 02714FZ, 02714G6, 02714GZ, 02714Z6, 02714ZZ, 02713E6, 
02714E6, 02723D6, 02723DZ, 02723F6, 02723EZ, 02723FZ, 02723GZ, 02723Z6, 02723ZZ, 
02724D6, 02724DZ, 02724EZ, 02724F6, 02724FZ, 02724G6, 02724GZ, 02724Z6, 02724ZZ, 
02723E602724E6, 02733D6, 02733DZ, 02733EZ, 02733F6, 02733FZ, 02733G6, 02733GZ, 
02733Z6, 02733ZZ, 02734D6, 02734DZ, 02734EZ, 02734F6, 02734FZ, 02734G6, 02734GZ, 
02734Z6, 02734ZZ, 02733E6, 02734E6, 02723E6, 02724E6, 02713E6, 02733E6, 02714E6, 
02734E6 
Bare metal stent 
02703E6, 02723E6, 02704E6, 02724E6 , 02713E6 , 02733E6, 02714E6, 02734E6 , 02703D6, 
02703DZ, 02723DZ, 02723D6, 02703EZ, 02703F6, 02703FZ, 02703G6, 02703GZ, 02723EZ, 
02723F6, 02723FZ, 02723G6, 02723GZ, 02723Z6, 02704D6, 02704DZ, 02704EZ, 02704F6, 
02724D6, 02724DZ, 02724EZ, 02724F6, 02704FZ, 02704GZ, 02724FZ, 02724G6, 02704G6, 
02724GZ, 02713D6, 02713DZ, 02713F6, 02713FZ, 02713G6, 02713GZ, 02733D6, 
02733DZ, 02733EZ, 02733F6, 02733FZ, 02733G6, 02733GZ, 02714D6, 02714DZ, 02714EZ, 
02714F6, 02714FZ, 02714G6, 02714GZ, 02734D6, 02734DZ, 02734EZ, 02734F6, 02734FZ, 
02734G6, 02734GZ, 02703E6, 02723E6, 02704E6, 02724E6, 02713E6, 02733E6, 02714E6, 
02734E6, 02703EZ, 02703F6, 02703FZ, 02703G6, 02703GZ, 02723EZ, 02723F6, 02723FZ, 
02723G6, 02723GZ, 02723Z6, 02704EZ, 02704F6, 02724EZ, 02724F6, 02704FZ, 02704G6, 
02704GZ, 02724FZ, 02724G6, 02724GZ, 02713F6, 02713FZ, 02713G6, 02713GZ, 02733EZ, 
02733F6, 02733FZ, 02733G6, 02733GZ, 02714EZ, 02714F6, 02714FZ, 02714G6, 02714GZ, 
02734EZ, 02734F6, 02734FZ, 02734G6, 02734GZ 
Coronary artery bypass 
grafting 
210093, 210098, 210099, 021009C, 021009F, 021009W, 02100A3, 02100A8, 02100A9, 
02100AC, 02100AF, 02100AW, 02100J3, 02100J8, 02100J9, 02100JC, 02100JF, 02100JW, 
02100K3, 02100K8, 02100K9, 02100KC, 02100KF, 02100KW, 02100Z3, 02100Z8, 
02100Z9, 02100ZC, 02100ZF, 211093, 211098, 211099, 021109C, 021109F, 021109W, 
02110A3, 02110A8, 02110A9, 02110AC, 02110AF, 02110J3, 02110J8, 02110J9, 02110JC, 
02110JF, 02110K3, 02110K8, 02110K9, 02110KC, 02110KF, 02110KW, 02110Z3, 
02110Z8, 02110Z9, 02110ZC, 02110ZF, 212093, 212098, 212099, 021209C, 021209F, 
021209W, 02120A3, 02120A8, 02120A9, 02120AC, 02120AF, 02120AW, 02120J3, 
02120J8, 02120J9, 02120JF, 02120JW, 02120K3, 02120K8, 02120K9, 02120KC, 02120KF, 
02120KW, 02120Z3, 02120Z8, 02120Z9, 02120ZC, 02120ZF, 213093, 213098, 213099, 
021309C, 021309F, 021309W, 02130A3, 02130A8, 02130A9, 02130AC, 02130AF, 
02130AW, 02130J3, 02130J8, 02130J9, 02130JC, 02130JF, 02130JW, 02130K3, 02130K8, 
02130K9, 02130KC, 02130KF, 02130KW, 02130Z3, 02130Z8, 02130Z9, 02130ZC, 02130ZF 
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Mechanical support 
devise other than intra-
aortic balloon pump 
02HA3RS, 02HA3RZ, 02HL3DZ, 5A0211D, 5A0221D, 5A15223 
Cardiogenic shock R570, T8110XA, T8111, T8111XA, T8111XS, T8119 
Acute ischemic stroke I63*, G43601, G43609, G43611, G43619, I97810, I97811, I97820, I97821 
Acute hemorrhagic stroke I60-I62 
Vascular complications 
S36899A, T81718A, T81719A, T8172XA, T81710A, T81711A, T801XXA, I770, S2500XA, 
S2501XA, S2502XA, S2509XA, S3500XA, S3501XA, S3502XA, S3509XA, S75011A, 
S75012A, S75019A, S75021A, S75022A, S75029A, S75099A, I97410, I97411, I97418, 
I9742, I97610, I97611, I97618, I97620, L7602, L7622, M96811, M96831, I9751, I9752, 
L7612, M96821, T8171, T8172, S25499A, S3559XA, S45001A, S45099A, S75001A, 
S75199A, S85001A, S85599A 
Blood transfusion 
30230H1, 30230J0, 30230J1, 30230K0, 30230K1, 30230L0, 30230L1, 30230M0, 30230M1, 
30230N0, 30230N1, 30230P0, 30230P1, 30230Q0, 30230Q1, 30230R0, 30230R1, 30230S0, 
30230S1, 30230T0, 30230T1, 30230V0, 30230V1, 30230W0, 30230W1, 30233H0, 30233H1, 
30233J0, 30233J1, 30233K0, 30233K1, 30233L0, 30233L1, 30233M0, 30233M1, 30233N0, 
30233N1, 30233P0, 30233P1, 30233Q0, 30233Q1, 30233R0, 30233R1, 30233S0, 30233S1, 
30233T0, 30233T1, 30233V0, 30233V1, 30233W0, 30233W1, 30240H0, 30240H1, 30240J0, 
30240J1, 30240K0, 30240K1, 30240L1, 30240L0, 30240M0, 30240M1, 30240N0, 30240N1, 
30240P0, 30240P1, 30240Q0, 30240Q1, 30240R0, 30240R1, 30240S0, 30240S1, 30240T0, 
30240T1, 30240V0, 30240V1, 30240W0, 30240W1, 30243H0, 30243H1, 30243J0, 30243J1, 
30243L0, 30243L1, 30243K0, 30243K1, 30243M0, 30243M1, 30243N0, 30243N1, 30243P0, 
30243P1, 30243Q0, 30243Q1, 30243R0, 30243R1, 30243S0, 30243S1, 30243T0, 30243T1, 
30243V0, 30243V1, 30243W0, 30243W1, 30250H0, 30250H1, 30250J0, 30250J1, 30250K0, 
30250K1, 30250L0, 30250L1, 30250M0, 30250M1, 30250N0, 30250N1, 30250Q0, 30250Q1, 
30250P0, 30250P1, 30250R0, 30250R1, 30250S0, 30250S1, 30250T0, 30250T1, 30250V0, 
30250V1, 30250W0, 30250W1, 30253H0, 30253H1, 30253J0, 30253J1, 30253K0, 30253K1, 
30253L0, 30253L1, 30253M0, 30253M1, 30253N0, 30253N1, 30253P0, 30253P1, 30253Q0, 
30253Q1, 30253R0, 30253R1, 30253S0, 30253S1, 30253T0, 30253T1, 30253V0, 30253V1, 
30253W0, 30253W1, 30260H0, 30260H1, 30260J0, 30260J1, 30260K0, 30260K1, 30260L0, 
30260L1, 30260M0, 30260M1, 30260N0, 30260N1, 30260P0, 30260P1, 30260Q0, 30260Q1, 
30260R0, 30260R1, 30260S0, 30260S1, 30260T0, 30260T1, 30260V0, 30260V1, 30260W0, 
30260W1, 30263H0, 30263H1, 30263J0, 30263J1, 30263K0, 30263K1, 30263L0, 30263L1, 
30263M0, 30263M1, 30263N0, 30263Q0, 30263Q1, 30263P0, 30263P1, 30263N1, 30263R0, 
30263R1, 30263T0, 30263T1, 30263V0, 30263V1, 30263W0, 30263W1, 30273H0, 
30273H1, 30273J0, 30273J1, 30273K0, 30273K1, 30273L0, 30273L1, 30273M0, 30273M1, 
30273N0, 30273Q0, 30273Q1, 30273P0, 30273P1, 30273N1, 30273R0, 30273R1, 30273T0, 
30273T1, 30273V0, 30273V1, 30273W0, 30273W1, 30277H1, 30277J1, 30277K1, 30277L1, 
30277M1, 30277Q1, 30277P1, 30277N1, 30277R1, 30277T1, 30277V1, 30277W1, 30280B1, 
30283B1, 3E030GC, 3E033GC, 3E040GC, 3E043GC, 3E050GC, 3E053GC, 3E060GC, 
3E063GC, 30230H0 
Gastrointestinal bleed 
I8501, I8511, K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, 
K276, K280, K282, K284, K286, K625, K920, K921, K922 
Mechanical ventilation 5A1935Z, 5A1945Z, 5A1955Z 
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Neoplasms 
C00-C14, C15-C26, C30-C39, C40-C41, C43-C58, C60-C80, C81-96, C7A, D00-D09, C4A*, 
C7B, C7B0, C7B00, C7B01, C7B02, C7B03, C7B04, C7B09, C7B1, C7B8, D10, D100, 
D101, D102, D103, D1030, D1039, D104, D105, D106, D107, D109, D11, D110, D117, 
D119, D12, D120, D121, D122, D123, D124, D125, D126, D127, D128, D129, D13, D130, 
D131, D132, D133, D1330, D1339, D134, D135, D136, D137, D139, D14, D140, D141, 
D142, D143, D1430, D1431, D1432, D144, D15, D150, D151, D152, D157, D159, D16, 
D160, D1600, D1601, D1602, D161, D1610, D1611, D1612, D162, D1620, D1621, D1622, 
D163, D1630, D1631, D1632, D164, D165, D166, D167, D168, D169, D17, D170, D171, 
D172, D1720, D1721, D1722, D1723, D1724, D173, D1730, D1739, D174, D175, D176, 
D177, D1771, D1772, D1779, D179, D18, D180, D1800, D1801, D1802, D1803, D1809, 
D181, D19, D190, D191, D197, D199, D20, D200, D201, D21, D210, D211, D2110, D2111, 
D2112, D212, D2120, D2121, D2122, D213, D214, D215, D216, D219, D22, D220, D221, 
D2210, D2211, D22111, D22112, D2212, D22121, D22122, D222, D2220, D2221, D2222, 
D223, D2230, D2239, D224, D225, D226, D2260, D2261, D2262, D227, D2270, D2271, 
D2272, D229, D23, D230, D231, D2310, D2311, D23111, D23112, D2312, D23121, 
D23122, D232, D2320, D2321, D2322, D233, D2330, D2339, D234, D235, D236, D2360, 
D2361, D2362, D237, D2370, D2371, D2372, D239, D24, D241, D242, D249, D25, D250, 
D251, D252, D259, D26, D260, D261, D267, D269, D27, D270, D271, D279, D28, D280, 
D281, D282, D287, D289, D29, D290, D291, D292, D2920, D2921, D2922, D293, D2930, 
D2931, D2932, D294, D298, D299, D30, D300, D3000, D3001, D3002, D301, D3010, 
D3011, D3012, D302, D3020, D3021, D3022, D303, D304, D308, D309, D31, D310, D3100, 
D3101, D3102, D311, D3110, D3111, D3112, D312, D3120, D3121, D3122, D313, D3130, 
D3131, D3132, D314, D3140, D3141, D3142, D315, D3150, D3151, D3152, D316, D3160, 
D3161, D3162, D319, D3190, D3191, D3192, D32, D320, D321, D329, D33, D330, D331, 
D332, D333, D334, D337, D339, D34, D35, D350, D3500, D3501, D3502, D351, D352, 
D353, D354, D355, D356, D357, D359, D36, D360, D361, D3610, D3611, D3612, D3613, 
D3614, D3615, D3616, D3617, D367, D369, D37, D370, D3701, D3702, D3703, D37030, 
D37031, D37032, D37039, D3704, D3705, D3709, D371, D372, D373, D374, D375, D376, 
D378, D379, D38, D380, D381, D382, D383, D384, D385, D386, D39, D390, D391, D3910, 
D3911, D3912, D392, D398, D399, D40, D400, D401, D4010, D4011, D4012, D408, D409, 
D41, D410, D4100, D4101, D4102, D411, D4110, D4111, D4112, D412, D4120, D4121, 
D4122, D413, D414, D418, D419, D42, D420, D421, D429, D43, D430, D431, D432, D433, 
D434, D438, D439, D44, D440, D441, D4410, D4411, D4412, D442, D443, D444, D445, 
D446, D447, D449, D45, D46, D460, D461, D462, D4620, D4621, D4622, D46A, D46B, 
D46C, D464, D46Z, D469, D47, D470, D4701, D4702, D4709, D471, D472, D473, D474, 
D47Z, D47Z1, D47Z2, D47Z9, D479, D48, D480, D481, D482, D483, D484, D485, D486, 
D4860, D4861, D4862, D487, D489, D3A, D3A0, D3A00, D3A01, D3A010, D3A011, 
D3A012, D3A019, D3A02, D3A020, D3A021, D3A022, D3A023, D3A024, D3A025, 
D3A026, D3A029, D3A09, D3A090, D3A091, D3A092, D3A093, D3A094, D3A095, 
D3A096, D3A098, D3A8, D49, D490, D491, D492, D493, D494, D495, D4951, D49511, 
D49512, D49519, D4959, D496, D497, D498, D4981, D4989, D499 
Irritable bowel syndrome K58* 
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Table S2. Comparison of Crude Rates of Clinical Outcome Between Men 
















In-hospital mortality 19.7% 8.0% <.001 18.3% 6.7% <.001 
Acute stroke 2.3% 1.1% <.001 1.5% 0.8% <.001 
Acute kidney injury 24.7% 15.9% <.001 29.7% 18.5% <.001 
New dialysis 1.2% 0.5% <.001 1.1% 0.5% <.001 
Vascular complications 1.2% 1.7% .06 1.1% 0.9% .37 
Gastrointestinal bleeding 3.0% 2.3% .06 3.3% 2.1% <.001 
Blood transfusion 7.8% 5.1% <.001 8.0% 3.7% <.001 
Mechanical ventilation 16.4% 11.3% <.001 19.8% 10.9% <.001 
Palliative care encounter 10.9% 2.7% <.001 8.2% 2.5% <.001 
Left against medical advice 0.7% 0.3% .002 1.0% 0.4% <.001 
Discharge home 46.6% 77.6% <.001 50.7% 82.6% <.001 
Non-home discharges 33.0% 14.1% <.001 29.9% 10.3% <.001 
Table S3. Comparison of Crude Rates of Clinical Outcome Between Men 
















In-hospital mortality 33.0% 15.0% <.001 31.0% 14.0% <.001 
Acute stroke 1.1% 1.4% .46 1.1% 0.9% .7 
Acute kidney injury 30.0% 24.0% <.001 35.0% 28.0% .001 
New dialysis 0.2% 0.3% .85 0.4% 1.4% .02 
Vascular complications 0.2% 1.7% <.001 0.4% 1.4% .01 
Gastrointestinal bleeding 3.6% 3.1% .44 3.0% 3.2% .8 
Blood transfusion 4.7% 6.7% .02 4.0% 5.1% .3 
Mechanical ventilation 8.5% 10.0% .14 12.0% 12.0% .66 
Palliative care encounter 28.0% 7.7% <.001 25.0% 6.6% <.001 
Left against medical advice 0.1% 0.3% .33 0.2% 0.7% .17 
Discharge home 31.0% 56.0% <.001 35.0% 65.0% <.001 





















In-hospital mortality 11.1% 3.6% <.001 11.9% 3.0% <.001 
Acute stroke 1.3% 0.6% .002 1.5% 0.5% <.001 
Acute kidney injury 14.5% 8.5% <.001 20.2% 11.0% <.001 
New dialysis 0.7% 0.3% .02 0.7% 0.3% .001 
Vascular complications 0.8% 1.2% .26 0.7% 0.6% .27 
Gastrointestinal bleeding 1.8% 1.0% .01 2.0% 1.1% <.001 
Blood transfusion 6.5% 3.8% <.001 5.7% 2.3% <.001 
Mechanical ventilation 16.0% 8.4% <.001 16.8% 7.9% <.001 
Palliative care encounter 4.8% 1.2% <.001 4.4% 1.0% <.001 
Left against medical advice 1.8% 0.6% <.001 2.4% 1.2% <.001 
Discharge home 68.8% 90.7% <.001 66.3% 91.1% <.001 
Non-home discharges 18.3% 4.9% <.001 19.3% 4.7% <.001 
Table S4. Comparison of Crude Rates of Clinical Outcome Between Men 
















In-hospital mortality 7.3% 2.8% <.001 5.9% 2.0% <.001 
Acute stroke 1.1% 0.6% .34 0.1% 0.4% .26 
Acute kidney injury 14.6% 7.4% <.001 14.6% 9.2% <.001 
New dialysis 0.4% 0.2% .58 0.7% 0.3% .16 
Vascular complications 0.7% 1.0% .64 0.4% 0.7% .43 
Gastrointestinal bleeding 2.6% 1.1% .07 1.5% 0.7% .04 
Blood transfusion 4.7% 4.3% .76 3.3% 1.9% .02 
Mechanical ventilation 12.0% 7.0% .008 10.4% 6.5% <.001 
Palliative care encounter 1.1% 1.3% .77 1.4% 0.8% .11 
Left against medical advice 3.6% 2.3% .19 3.5% 1.5% <.001 
Discharge home 71.5% 90.7% <.001 78.3% 93.5% <.001 
Non-home discharges 17.2% 4.2% <.001 12.1% 2.9% <.001 
Table S5.  Comparison of Crude Rates of Clinical Outcome Between Men 












ATE (95 CI) P* ATE (95 CI) P* 
In-hospital mortality -15.2% (-18.6%, -
11.8%) 
<.001 -17.5% (-22.4%, -
12.5%) 
<.001 .46 
Acute stroke 4.8% (1.7%, 8.0%) .002 2.2% (-1.9%, 6.3%) .301 .31 
Acute renal failure 0.2% (-0.9%, 1.2%) .729 -0.4% (-1.4%, 0.5%) .371 .39 
New dialysis -1.5% (-5.0%, 2.0%) .401 -0.8% (-5.6%, 4.0%) .752 .81 
Vascular complications -0.1% (-0.4%, 0.3%) .732 1.2% (0.3%, 2.0%) .009 .01 
Gastrointestinal bleeding 1.4% (0.5%, 2.3%) .003 1.1% (0.3%, 1.9%) .007 .65 
Blood transfusion -0.8% (-2.2%, 0.6%) .259 0.2% (-1.6%, 2.0%) .822 .39 
Mechanical ventilation 1.7% (-0.3%, 3.7%) .091 1.5% (-0.6%, 3.5%) .160 .86 
Palliative care encounter 1.5% (-1.2%, 4.1%) .280 -3.8% (-7.6%, 0.0%) .049 .03 
Left against medical advice -17.1% (-20.0%, -
14.2%) 
<.001 -15.1% (-18.9%, -
11.2%) 
<.001 .41 
Discharge home 0.1% (-0.1%, 0.3%) .329 0.8% (0.0%, 1.5%) .043 .09 
Non-home discharges 21.9% (17.8%, 26.0%) <.001 26.0% (20.4%, 31.6%) <.001 .25 
* This P value indicates the significance of ATE against the null hypothesis of no effect (ATE=0%) 
within each group.
**This P value indicates the significance of ATE difference between males and females. We used 
z-score= (B1 - B2) / √ (seB1^2 + seB2^2) to compare average treatment effects between groups.
Table S6.  Average Treatment Effect of PCI in Men and Women age 85-years or above 












ATE (95 CI) P* ATE (95 CI) P* 
In-hospital mortality -9.4% (-11.3%, -7.5%) <.001 -9.6% (-11.0%, -8.3%) <.001 0.85 
Acute stroke -0.9% (-2.9%, 1.2%) .41 -1.8% (-3.2%, -0.3%) 0.019 0.48 
Acute renal failure -1.0% (-1.8%, -0.2%) .011 -0.4% (-0.9%, 0.1%) 0.11 0.20 
New dialysis -4.1% (-6.1%, -2.1%) <.001 -4.1% (-5.6%, -2.6%) <.001 0.98 
Vascular complications -0.2% (-0.6%, 0.2%) .28 -0.2% (-0.5%, 0.1%) 0.193 0.97 
Gastrointestinal bleeding 0.4% (-0.2%, 1.0%) .19 0.1% (-0.3%, 0.4%) 0.79 0.34 
Blood transfusion 0.2% (-0.8%, 1.2%) .66 -0.7% (-1.4%, 0.0%) 0.039 0.12 
Mechanical ventilation -1.2% (-2.4%, 0.0%) .05 -3.2% (-4.2%, -2.2%) <.001 0.01 
Palliative care encounter -3.5% (-5.3%, -1.7%) <.001 -6.5% (-8.0%, -5.0%) <.001 0.01 
Left against medical advice -5.8% (-7.1%, -4.5%) <.001 -3.7% (-4.6%, -2.9%) <.001 0.01 
Discharge home -0.4% (-0.7%, 0.0%) .038 -0.7% (-1.1%, -0.3%) 0.001 0.19 
Non-home discharges 26.6% (24.1%, 29.2%) <.001 27.8% (25.9%, 29.8%) <.001 0.46 
* This P value indicates the significance of ATE against the null hypothesis of no effect (ATE=0%) 
within each group.
**This P value indicates the significance of ATE difference between males and females. We used 
z-score= (B1 - B2) / √ (seB1^2 + seB2^2) to compare average treatment effects between groups.
Table S7. Average Treatment Effect of PCI in Men and Women age 65-84 years Who 












ATE (95 CI) P* ATE (95 CI) P* 
In-hospital mortality -5.3% (-6.9%, -3.7%) <.001 -7.2% (-8.2%, -6.1%) <.001 .056 
Acute stroke -0.6% (-2.5%, 1.4%) .577 -1.9% (-3.1%, -0.7%) .002 .26 
Acute renal failure -0.6% (-1.2%, 0.0%) .035 -0.7% (-1.1%, -0.3%) .001 .9 
New dialysis -2.2% (-3.9%, -0.5%) .011 -3.2% (-4.4%, -1.9%) <.001 .34 
Vascular complications -0.1% (-0.5%, 0.2%) .5 -0.1% (-0.4%, 0.2%) .410 .97 
Gastrointestinal bleeding 0.1% (-0.7%, 0.8%) .851 0.1% (-0.2%, 0.3%) .654 .99 
Blood transfusion -0.2% (-0.8%, 0.4%) .565 -0.4% (-0.8%, 0.0%) .064 .59 
Mechanical ventilation -0.9% (-2.2%, 0.4%) .163 -2.0% (-2.7%, -1.2%) <.001 .15 
Palliative care encounter -4.9% (-6.8%, -3.0%) <.001 -5.4% (-6.6%, -4.2%) <.001 .64 
Left against medical advice -2.8% (-3.9%, -1.8%) <.001 -2.4% (-3.1%, -1.8%) <.001 .52 
Discharge home -1.1% (-1.8%, -0.4%) .002 -0.9% (-1.5%, -0.4%) .001 .77 
Non-home discharges 20.5% (17.8%, 23.2%) <.001 22.0% (20.2%, 23.7%) <.001 .38 
* This P value indicates the significance of ATE against the null hypothesis of no effect (ATE=0%) 
within each group.
**This P value indicates the significance of ATE difference between males and females. We used 
z-score= (B1 - B2) / √ (seB1^2 + seB2^2) to compare average treatment effects between groups.
Table S8. Average Treatment Effect of PCI in Men and Women age 45-64 years Who 












ATE (95 CI) P* ATE (95 CI) P* 
In-hospital mortality -3.7% (-6.0%, -1.5%) .001 -2.1% (-4.0%, -0.2%) .028 .28 
Acute stroke 3.8% (0.7%, 6.9%) .015 1.6% (-0.5%, 3.6%) .148 .23 
Acute renal failure -0.7% (-3.7%, 2.3%) .662 0.3% (-0.1%, 0.7%) .101 .52 
New dialysis -6.1% (-10.7%, -1.5%) .009 -1.7% (-4.8%, 1.4%) .283 .12 
Vascular complications 0.0% (-0.7%, 0.7%) 1.000 -0.1% (-0.6%, 0.4%) .672 .81 
Gastrointestinal bleeding 0.3% (-0.9%, 1.5%) .643 0.1% (-0.8%, 0.9%) .868 .78 
Blood transfusion -1.5% (-3.8%, 0.8%) .190 0.1% (-0.5%, 0.8%) .651 .17 
Mechanical ventilation -0.3% (-4.1%, 3.6%) .888 0.1% (-1.3%, 1.4%) .930 .87 
Palliative care encounter -3.6% (-8.3%, 1.1%) .129 -0.9% (-3.2%, 1.4%) .453 .30 
Left against medical advice 0.6% (-0.6%, 1.7%) .356 0.0% (-0.8%, 0.7%) .912 .40 
Discharge home -1.6% (-3.9%, 0.8%) .190 -1.5% (-3.1%, 0.2%) .077 .95 
Non-home discharges 17.8% (10.5%, 25.0%) <.001 13.0% (9.2%, 16.8%) <.001 .25 
* This P value indicates the significance of ATE against the null hypothesis of no effect (ATE=0%) 
within each group.
**This P value indicates the significance of ATE difference between males and females. We used 
z-score= (B1 - B2) / √ (seB1^2 + seB2^2) to compare average treatment effects between groups.
Table S9.  Average Treatment Effect of PCI in Men and Women age <45 years Who 
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Table S10.  Comparison of Crude Rates of Clinical Outcome Between Men 
and Women Stratified by pPCI Use Excluding Patients with Elective 
















In-hospital mortality 20.5% 6.6% <.001 16.0% 4.5% <.001 
Acute stroke 1.7% 0.9% <.001 1.4% 0.6% <.001 
Acute kidney injury 23.1% 13.3% <.001 25.3% 14.0% <.001 
New dialysis 0.8% 0.4% <.001 0.8% 0.4% <.001 
Vascular complications 0.8% 1.4% <.001 0.8% 0.7% .368 
Gastrointestinal bleeding 2.8% 1.8% <.001 2.6% 1.4% <.001 
Blood transfusion 6.5% 4.7% <.001 6.1% 2.8% <.001 
Mechanical ventilation 14.2% 9.9% <.001 17.6% 9.0% <.001 
Palliative care encounter 13.6% 2.5% <.001 7.5% 1.6% <.001 
Left against medical advice 0.9% 0.5% 0.002 1.8% 0.9% <.001 
Discharge home 49.3% 81.9% <.001 57.6% 87.7% <.001 












ATE (95 CI) P* ATE (95 CI) P* 
In-hospital mortality -9.2% (-10.4%, -8.1%) <.001 -7.9% (-8.7%, -7.2%) <.001 .08 
Acute stroke 0.3% (-1.0%, 1.6%) .65 -1.2% (-2.1%, -0.4%) .006 .05 
Acute renal failure -0.6% (-1.0%, -0.1%) .01 -0.4% (-0.7%, -0.2%) .002 .56 
New dialysis -3.1% (-4.3%, -1.9%) <.001 -3.5% (-4.4%, -2.5%) <.001 .65 
Vascular complications -0.2% (-0.4%, 0.1%) .12 0.0% (-0.1%, 0.2%) .61 .11 
Gastrointestinal bleeding 0.6% (0.2%, 1.0%) .005 0.0% (-0.2%, 0.2%) .97 .01 
Blood transfusion -0.2% (-0.7%, 0.3%) .52 -0.4% (-0.7%, 0.0%) .044 .54 
Mechanical ventilation -0.9% (-1.7%, 0.0%) .042 -2.1% (-2.6%, -1.5%) <.001 .02 
Palliative care encounter -3.3% (-4.6%, -2.1%) <.001 -5.4% (-6.3%, -4.5%) <.001 .01 
Left against medical advice -6.1% (-6.9%, -5.2%) <.001 -3.2% (-3.7%, -2.7%) <.001 .00 
Discharge home -0.4% (-0.7%, 0.0%) .045 -0.7% (-1.1%, -0.4%) <.001 .16 
Non-home discharges 23.8% (22.1%, 25.5%) <.001 23.9% (22.7%, 25.1%) <.001 .93 
* This P value indicates the significance of ATE against the null hypothesis of no effect (ATE=0%) 
within each group.
**This P value indicates the significance of ATE difference between males and females. We used 
z-score= (B1 - B2) / √ (seB1^2 + seB2^2) to compare average treatment effects between groups.
Table S11.  Average Treatment Effect of PCI in Men and Women Who Presented with 
STEMI using Propensity Score Matching Excluding Patients with Elective Admissions 
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Table S12. Comparison of Crude Rates of Clinical Outcome Between Men 
and Women Stratified by pPCI Use Excluding Patients with Coronary 


















In-hospital mortality 21.7% 6.5% <.001 15.8% 4.4% <.001 
Acute stroke 1.7% 0.9% <.001 1.4% 0.6% <.001 
Acute kidney injury 23.9% 13.1% <.001 25.1% 13.9% <.001 
New dialysis 0.8% 0.4% <.001 0.8% 0.4% <.001 
Vascular complications 0.8% 1.4% .001 0.8% 0.7% .340 
Gastrointestinal bleeding 2.9% 1.8% <.001 2.6% 1.5% <.001 
Blood transfusion 6.8% 4.6% <.001 6.4% 2.8% <.001 
Mechanical ventilation 14.3% 9.7% <.001 17.3% 8.9% <.001 
Palliative care encounter 14.3% 2.4% <.001 7.5% 1.6% <.001 
Left against medical advice 0.9% 0.5% .004 1.7% 0.9% <.001 
Discharge home 47.0% 81.9% <.001 57.8% 87.8% <.001 












ATE (95 CI) P* ATE (95 CI) P* 
In-hospital mortality -10.1% (-11.3%, -8.9%) <.001 -8.0% (-8.8%, -7.2%) <.001 <.01 
Acute stroke -0.1% (-1.3%, 1.2%) .94 -1.2% (-2.1%, -0.4%) .005 .13 
Acute renal failure -0.8% (-1.3%, -0.4%) .001 -0.4% (-0.7%, -0.2%) .002 .11 
New dialysis -3.1% (-4.4%, -1.9%) <.001 -3.3% (-4.3%, -2.4%) <.001 .8 
Vascular complications -0.4% (-0.6%, -0.1%) .006 0.0% (-0.2%, 0.1%) .891 .02 
Gastrointestinal bleeding 0.6% (0.2%, 1.0%) .001 0.0% (-0.2%, 0.2%) .786 <.01 
Blood transfusion -0.3% (-0.8%, 0.3%) .3 -0.2% (-0.6%, 0.1%) .137 .88 
Mechanical ventilation -1.3% (-2.2%, -0.3%) .009 -2.1% (-2.6%, -1.6%) <.001 .12 
Palliative care encounter -4.0% (-5.3%, -2.7%) <.001 -5.4% (-6.2%, -4.5%) <.001 .09 
Left against medical advice -6.9% (-7.8%, -6.0%) <.001 -3.2% (-3.7%, -2.7%) <.001 <.01 
Discharge home -0.6% (-1.0%, -0.2%) .008 -0.7% (-1.0%, -0.4%) <.001 .66 
Non-home discharges 25.2% (23.4%, 26.9%) <.001 23.9% (22.7%, 25.1%) <.001 .24 
* This P value indicates the significance of ATE against the null hypothesis of no effect (ATE=0%) 
within each group.
**This P value indicates the significance of ATE difference between males and females. We used 
z-score= (B1 - B2) / √ (seB1^2 + seB2^2) to compare average treatment effects between groups.
Table S13. Average Treatment Effect of PCI in Men and Women Who Presented with 












ATE P ATE P 
Irritable Bowel Syndrome 0.0% (-0.4%, 0.3%) .37 0.0% (-0.1%, 0.2%) .87 .69 
Infectious arthropathy 0.01% (-0.04%, 0.06%) .52 -0.02% (-0.07%, 0.04%) .62 .42 
AME P AME P 
Irritable Bowel Syndrome 0.0% (-0.3%, 0.3%) .77 0.0% (-0.1%, 0.1%) .78 .60 
Infectious arthropathy -0.01% (-0.10%, 0.08%) .77 -0.01% (-0.05%, 0.03%) .63 .93 
Table S14. Average Treatment Effect and Average Marginal Effect 
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Figure S1. Distribution of Standardized Differences Before and After Propensity 
Score Matching 
COPD; chronic obstructive lung disease, PVD; peripheral vascular disease, Afib; atrial 
fibrillation, CHF; congestive heart failure, DM; diabetes, HTN; hypertension, CKD; chronic 
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